Treatment efficacy and glucose variability control of exenatide versus biphasic insulin aspart 30 in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, open-label, parallel study

被引：0
|
作者：
Liu, Xiangyang [1 ]
Ji, Qiuhe [1 ]
Yang, Wenjuan [2 ]
Liu, Jianrong [3 ]
Gao, Xiling [4 ]
He, Qingzhen [5 ]
Ma, Kaiyan [6 ]
Tian, Zhufang [7 ]
Xie, Xuan [8 ]
机构：
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian, Shaanxi, Peoples R China
[2] Shaanxi Aerosp Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[3] Xian Chang An Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[4] Yanan Peoples Hosp, Dept Endocrinol, Yanan, Shannxi Provinc, Peoples R China
[5] Xian Gaoxin Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[6] Shangluo Cent Hosp, Dept Endocrinol, Shangluo, Shannxi Provinc, Peoples R China
[7] Xian Cent Hosp, Dept Endocrinol, Xian, Shannxi Provinc, Peoples R China
[8] Xi An Jiao Tong Univ, Dept Endocrinol, Affiliated Hosp 2, Xian, Shannxi Provinc, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2018年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1053987
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    Rosenstock, Julio
    Raccah, Denis
    Koranyi, Laszlo
    Maffei, Laura
    Boka, Gabor
    Miossec, Patrick
    Gerich, John E.
    DIABETES CARE, 2013, 36 (10) : 2945 - 2951
  • [42] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [43] Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)
    Gao, Bin
    Gao, Weiguo
    Wan, Hailong
    Xu, Fengmei
    Zhou, Rong
    Zhang, Xia
    Ji, Qiuhe
    DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 991 - 999
  • [44] Treatment with biphasic insulin aspart 30 improves glycaemic control in patients with Type 2 diabetes inadequately controlled with oral antidiabetic drugs: results from China cohort in the PRESENT study
    Gao, Yan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S64 - S65
  • [45] Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J 2013; 37: 11724)
    Song, Kee-Ho
    Kim, Jung Min
    Noh, Jung-Hyun
    Park, Yongsoo
    Son, Hyun-Shik
    Min, Kyong Wan
    Ko, Kyung Soo
    DIABETES & METABOLISM JOURNAL, 2013, 37 (03) : 214 - 215
  • [46] Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
    Gautam, Kumar
    Tripathy, Ratikanta
    Meher, Dayanidhi
    Sahoo, Jyoti Prakash
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (04)
  • [47] Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes
    Clements, Michael R.
    Tits, J.
    Kinsley, B. T.
    Rastam, J.
    Friberg, H. H.
    Ligthelm, R. J.
    DIABETES OBESITY & METABOLISM, 2008, 10 (03): : 229 - 237
  • [48] Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart
    Wolnik, Bogumil
    Hak, Lukasz
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (02) : 137 - 144
  • [49] In patients with poorly controlled Type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination
    Kvapil, M
    Mikolajczyk-Swatko, A
    Ostergaard, AH
    Shestakova, M
    DIABETOLOGIA, 2002, 45 : A18 - A18
  • [50] Vildagliptin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy: efficacy and tolerance at 52 weeks
    Halimi, S.
    Dejager, S.
    Arnou, R.
    Delamare, G.
    Ferrannini, E.
    DIABETES & METABOLISM, 2009, 35 : A8 - A8
12345